Conference Coverage

ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression

The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Sacituzumab Govitecan Achieves 29 Percent ORR in Advanced Urothelial Cancer

Interim data from a 100-patient cohort of cisplatin-eligible patients participating in the TROPHY-U-01, an international, multi-center, open-label, phase II...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Phase I/IIa Trial Evaluating BT1718 Shows Encouraging Progress in Dose Escalation Phase

Updated data from a Phase I/IIa trial evaluating BT1718, a Bicycle Toxin Conjugate being developed Bicycle Therapeutics, was presented...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer Did Not Meet...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Combination of Enfortumab Vedotin + Pembrolizumab Shows High ORR in Urothelial Cancer

Initial results from EV-103, a phase I clinical trial (NCT03288545) of the investigational antibody-drug conjugate enfortumab vedotin (also known...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase I Trial Results...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO),...

Dose Escalation Shows DS-1062 to be Well-tolerated with Partial, Dose-dependent, Responses

Results of a Phase I clinical study and new biomarker data for DS-1062 in 52 unselected patients...

Late-breaking Results: HER3 Targeting U3-1402 in Patients with Metastatic EGFR Mutated, TKI Resistant NSCLC...

Updated phase I data for U3-1402, an investigational HER3 targeting antibody-drug conjugate or ADC being developed by...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and DS-1062 Studies

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung...